Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms,diagnosis, and management
作者机构：Department of Biotherapy and Cancer CenterWest China HospitalSichuan UniversityChengdu 610041Sichuan ProvinceChina West China Medical PublishersWest China Hospital of Sichuan UniversityChengdu 610041Sichuan ProvinceChina Department of OncologyWest China Hospitalthe First People’s Hospital of Long Quan Yi DistrictChengdu 610041Sichuan ProvinceChina
出 版 物：《International Journal of Ophthalmology(English edition)》 (国际眼科杂志（英文版）)
年 卷 期：2022年第15卷第4期
页 面：646-656页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：immune checkpoint inhibitor ophthalmological adverse events uveitis neuro-ophthalmic toxicity retinopathy
摘 要：Immune checkpoint inhibitors(ICIs) targeting cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 receptor/ligand have revolutionized cancer treatment, achieving unprecedented efficacy in numerous malignancies. Despite the excellent therapeutic effects of ICIs, medications, such as pembrolizumab, ipilimumab, nivolumab, atezolizumab, avelumab, and durvalumab, typically cause a broad spectrum of toxicity events termed as immune-related adverse events(ir AEs). Out of all ir AEs, ophthalmic adverse events occur infrequently and are not comprehensively recognized. The current understanding of ophthalmic ir AEs is mainly derived from case reports and case series. In this review, based on relevant articles in the literature and current evidence, we summarize the incidences, manifestations, diagnoses, underlying mechanisms, treatments, and outcomes of ophthalmic ir AEs and discuss possible management strategies. A better understanding of these features is critical for managing patients with ICI-associated ophthalmic adverse events.
维普期刊数据库